Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ipsen Strengthens Early Clinical Pipeline With IRLAB’s Mesdepotem For Levodopa-Induced Dyskinesia

Upfront Of $28m

Executive Summary

Ipsen has gained worldwide development and commercialization rights to IRLAB’s dopamine D3 antagonist, mesdepotem, in levodopa-induced dyskinesia in Parkinson’s disease.

You may also be interested in...



Ipsen Buys Into BAX Inhibitor, Targeting Certain Cancers

Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.

Deal Watch: AstraZeneca Out-Licenses Pneumonia Candidate, Obtains STING Inhibitors

Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.

Ipsen's Sales Growth Could Be Held Back By Generics And Currency In 2021

France’s Ipsen reports a solid financial performance in 2020 but is cautious about guidance for 2021, as the mid-sized pharmaceutical company’s next rare disease candidate nears the market and it looks for early-stage assets to add to its pipeline.  

Topics

Related Companies

UsernamePublicRestriction

Register

SC144736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel